Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
GLP-1 (Glucagon-like Peptide-1) is a natural incretin hormone that: Stimulates insulin secretion (when glucose is high) Suppresses glucagon release Slows gastric emptying Increases satiety reducing food intake Why GLP-1 Therapy Stands Out Glycemic Control Lowers HbA1c by ~11.5% with minimal hypoglycemia risk Weight Loss 515 kg depending on drug/dose (semaglutide leads the way) Cardiovascular Protection Reduced major CV events (MACE) in trials like LEADER, SUSTAIN, REWIND Renal Protection Slows progression of diabetic kidney disease Convenience Available as daily or weekly injections and even oral semaglutide Key Clinical Trials LEADER (Liraglutide) CV mortality & MACE SUSTAIN-6 (Semaglutide) CV events & strong weight loss REWIND (Dulaglutide) CV protection even in lower-risk populations STEP Trials (Semaglutide) Double-digit weight reduction in obesity The Bigger Picture GLP-1 therapy goes beyond insulin and beyond diabetes
It involves genes, lifestyle, and health
Bright-field multiplex immunohistochemistry assay for tumor microenvironment evaluation in melanoma tissues
4.6 Closing remarks According to the ACLM (60), there are several key behaviors, including core competencies with the minimum of the dual approach to sustainable health: Eating healthy food before taking medication (i.e., Food over Medicine), and continuously linked to Moderate-to-high levels of day-to-day PA, sports, and exercise (i.e., Exercise over Medicine)
US$ 21.93
US$ 20.65
US$ 22.56
